Official websites use. Share sensitive information only on official, secure websites. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source.
All content was reviewed and approved by the EBMT Committee, which held full responsibility for the abstract selections. Background: Post-transplant cyclophosphamide PTCy -based anti-GVHD prophylaxis pioneered in haploidentical Haplo transplantation is being increasingly used in other transplantation settings. Median follow-up was 24 range, Engraftment day 60 was Sequential conditioning regimens e.
A recent retrospective analysis showed promising survival data in younger patients conditioned with high dose melphalan, followed by 8 Gy TBI and fludarabine, while for elderly patients this intense therapy was associated with significant toxicities.
Thirteen patients were initially diagnosed with favorable risk, 37 patients with intermediate risk, and 49 patients with adverse risk AML ELN Median follow-up of surviving patients was days after transplant. Cumulative incidences C. Background: The best stem cell source for T-cell replete HLA-haploidentical transplantation with post-transplant cyclophosphamide PTCy remains to be determined.
In patients with active acute myeloid leukemia AML at transplantation, one could speculate that the use of peripheral blood stem cells PBSC versus bone marrow BM could be associated with higher graft-versus-leukemia effects.
